Table 1.
The miRNA-regulating activity levels in in vitro studies depending on the different enoxacin concentrations.
| miRNA | Conc. [µM] | Effect | Expression Change | Cell Line | Ref. |
|---|---|---|---|---|---|
| [↑/↓] | Change-Fold | ||||
| Cancer cells | |||||
| let-7b-5p, miR-146a-5p, miR-689 | 50 | ↓ | 0.5–1 | 4T1 (miRNA from EV), | [49] |
| miR-100 | 124 | ↓ | 0.5–1 | primary ESFT spheres | [37] |
| miR-141, miR-191 | 124 | ↓ | 1.5–2 | DU145, LNcap, | [38] |
| miR-21-5p, miR-30a-3p, miR-30a-5p, miR-100-5p, miR-204-5p, miR-221-3p | 124 | ↑ | <1.5 | Cal62, STA-ET-8.2, TPC1 | [39] |
| Let-7f, miR-26a, | 124 | ↑ | <1.5 | A673, SW1736 | [37] |
| miR-21 | 100 | ↑ | 1.5–2 | MCF7 | [41] |
| miR-16, miR-18a*, miR-21, miR-26a, miR-29b, miR-29c, miR-31, miR-193a, | 124 | ↑ | 1.5–2 | HCT-116 | [36] |
| let-7f, miR-26a, miR-99a, miR-100, miR-143, miR-145, | 124 | ↑ | 1.5–2 | A673, STA-ET-8.2, TC252, primary ESFT spheres | [37] |
| miR-21-5p, miR-30a-3p, miR-100-5p, miR-146b-5p, miR-221-3p, | 124 | ↑ | 1.5–2 | Cal62, SW1736, TPC1 | [39] |
| miR-17 *, miR29b, miR-132, miR-146a, miR-191 miR-449a, | 124 | ↑ | 1.5–2 | DU145 LNcap, | [38] |
| miR-214-3p | 50 | ↑ | 2–2.5 | 4T1 (cytosolic miRNA), | [49] |
| miR-145 | 100 | ↑ | 2–2.5 | MCF7 | [41] |
| miR-7, miR-16, miR-18a*, miR-29c, miR-101, miR-128, miR-181a, miR-212 | 124 | ↑ | 2–2.5 | HCT-116, RKO | [36] |
| miR-100-5p, miR-146b-5p | 124 | ↑ | 2–2.5 | SW1736, TPC1 | [39] |
| miR-34a, miR-449a | 124 | ↑ | 2–2.5 | DU145, LNcap | [38] |
| let-7f, miR-99a, miR-100, miR-145 | 124 | ↑ | 2–2.5 | A673, STA-ET-8.2, TC252, primary ESFT spheres | [37] |
| miR-7, miR-26a, miR-29b, miR-30a, miR-101, miR-122, miR-125a, miR-125b, miR-126, miR-128, miR-143, miR-181b, miR-205 | 124 | ↑ | 2.5–3 | HCT-116, RKO | [36] |
| miR-100, miR-145 | 124 | ↑ | 2.5–3 | A673, TC252 | [37] |
| miR-29b | 124 | ↑ | 2.5–3 | LNcap | [38] |
| let-7a, let-7b, miR-30a, miR-31, miR-126, miR-181b, miR-193a, miR-193b, | 124 | ↑ | 3–3.5 | HCT-116, RKO | [36] |
| let-7f, miR-143, miR-181a, | 124 | ↑ | 3–3.5 | A673, STA-ET-8.2, primary ESFT spheres | [37] |
| miR-181a, miR-193b | 124 | ↑ | 3.5–4 | HCT-116 | [36] |
| let-7b, miR-143, miR-205 | 124 | ↑ | 4–4.5 | HCT-116, RKO | [36] |
| miR-143 | 124 | ↑ | 4–4.5 | TC252 | [37] |
| miR-125a | 124 | ↑ | ca. 5 | HCT-116 | [36] |
| miR-214-3p | 50 | ↑ | ca. 22 | 4T1 (miRNA from EV) | [49] |
| Non-cancer cells | |||||
| miR-128-1 | 60 | ↓ | 0.5–1 | dnTGFβRII T cells | [65] |
| let-7i, miR-128 | 50 | ↓ | 1.5–2 | HEK293 | [35] |
| let-7b, miR-23a, miR-30e, miR-96, miR-99a, miR-125a, miR-146, miR-190, miR-199a*, | 50 | ↑ | 1.5–2 | HEK293 | [35] |
| miR-124a, miR-139, miR-152, miR-199b | 50 | ↑ | 2–2.5 | HEK293 | [35] |
| miR-29b-1, miR-145a-5p, miR-326-3p | 60 | ↑ | 2–2.5 | dnTGFβRII T cells | [65] |
| miR-181a | 60 | ↑ | 2.5–3 | dnTGFβRII T cells | [65] |
| miR-346-5 | 60 | ↑ | 3–3.5 | dnTGFβRII T cells | [65] |
Dominant negative TGF-β receptor (dnTGFβRII). Please note that “*” is not a footnote indicator, but an essential part of the name of the specific miRNA. More information regarding the miRNAs’ nomenclature can be found in miRBase [68].